Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08PFA
|
|||
| Former ID |
DIB016579
|
|||
| Drug Name |
Rivoglitazone
|
|||
| Synonyms |
CS-011; DE-101; Rivoglitazone (ophthalmic); Rivoglitazone (ophthalmic), Santen; CS-011 (ophthalmic), Santen
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Ocular inflammation [ICD-11: 9C61.24; ICD-10: H40.4; ICD-9: 370.33] | Phase 3 | [1] | |
| Company |
Sankyo Co Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H19N3O4S
|
|||
| Canonical SMILES |
CN1C2=C(C=CC(=C2)OC)N=C1COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4
|
|||
| InChI |
1S/C20H19N3O4S/c1-23-16-10-14(26-2)7-8-15(16)21-18(23)11-27-13-5-3-12(4-6-13)9-17-19(24)22-20(25)28-17/h3-8,10,17H,9,11H2,1-2H3,(H,22,24,25)
|
|||
| InChIKey |
XMSXOLDPMGMWTH-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 185428-18-6
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00571519) Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus. U.S. National Institutes of Health. | |||
| REF 2 | A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes. Diabetes Obes Metab. 2011 Sep;13(9):806-13. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.